Sage Therapeutics/Biogen's episodic therapy zuranolone could change MDD treatment

By Yahoo! Finance | Jul 22, 2024 at 02:00 AM EST

Sage Therapeutics and Biogen's zuranolone, a novel antidepressant for MDD, showed positive results in a Phase III trial. The drug's rapid response treatment offers a new mechanism of action in a competitive market, addressing the need for fast-acting therapies.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.